The Cooper Companies, Inc.·Healthcare
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Healthcare
Medical - Instruments & Supplies
16,000
1983-01-21
0.89

Investors with an interest in Medical - Dental Supplies stocks have likely encountered both The Cooper Companies (COO) and Straumann Holding AG (SAUHY). But which of these two stocks is more attractive to value investors?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Investors interested in Medical - Dental Supplies stocks are likely familiar with The Cooper Companies (COO) and Straumann Holding AG (SAUHY). But which of these two stocks is more attractive to value investors?

SAN RAMON, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today that its Board of Directors has appointed Paul Keel as an independent director, effective July 1, 2026. Mr. Keel has also been appointed to serve on the Audit Committee when he joins the Board.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

25,949 shares of Common Stock were sold directly on April 17, 2026, for an estimated ~$903,000 at around $34.79 per share. This transaction represented 0.68% of Tamari's direct holdings, reducing direct ownership to 3,790,225 shares post-sale.